Literature DB >> 14568343

Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes.

Tadimeti S Rao1, Karen D Lariosa-Willingham, Fen-Fen Lin, Emma L Palfreyman, Naichen Yu, Jerold Chun, Michael Webb.   

Abstract

Lysophosphatidic acid (1-acyl-2-lyso-sn-glycero-3-phosphate; LPA) and sphingosine-1-phosphate (S1P) are bioactive phospholipids which respectively act as agonists for the G-protein-coupled lpA receptors (LPA1, LPA2, and LPA3) and s1p receptors (S1P1, S1P2, S1P3, S1P4, and S1P5), collectively referred to as lysophospholipid receptors (lpR). Since astrocytes are responsive to LPA and S1P, we examined mechanisms of lpR signaling in rat cortical secondary astrocytes. Rat cortical astrocyte mRNA expression by quantitative TaqMan polymerase chain reaction (PCR) analysis revealed the following order of relative expression of lpR mRNAs: s1p3>s1p1>lpa1>s1p2=lpa3>>s1p5. Activation of lpRs by LPA or S1P led to multiple pharmacological effects, including the influx of calcium, phosphoinositide (PI) hydrolysis, phosphorylation of extracellular receptor regulated kinase (ERK) and release of [3H]-arachidonic acid (AA). These signalling events downstream of lpR activation were inhibited to varying degrees by pertussis toxin (PTX) pretreatment or by the inhibition of sphingosine kinase (SK), a rate-limiting enzyme in the biosynthesis of S1P from sphingosine. These results suggest that astrocyte lpR signalling mechanisms likely involve both Gi- and Gq-coupled GPCRs and that receptor-mediated activation of SK leads to intracellular generation of S1P, which in turn amplifies the lpR signalling in a paracrine/autocrine manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568343     DOI: 10.1016/s0006-8993(03)03527-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  35 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 3.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

Review 4.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

5.  Sphingosine-1-phosphate and calcium signaling in cerebellar astrocytes and differentiated granule cells.

Authors:  Paola Giussani; Anita Ferraretto; Claudia Gravaghi; Rosaria Bassi; Guido Tettamanti; Laura Riboni; Paola Viani
Journal:  Neurochem Res       Date:  2006-12-07       Impact factor: 3.996

Review 6.  Neuron-astroglial interactions in cell-fate commitment and maturation in the central nervous system.

Authors:  Joice Stipursky; Tânia Cristina Leite de Sampaio E Spohr; Vivian Oliveira Sousa; Flávia Carvalho Alcantara Gomes
Journal:  Neurochem Res       Date:  2012-05-22       Impact factor: 3.996

Review 7.  Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.

Authors:  Matthias Mehling; Ludwig Kappos; Tobias Derfuss
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

8.  Anatomical location of LPA1 activation and LPA phospholipid precursors in rodent and human brain.

Authors:  Estibaliz González de San Román; Iván Manuel; María Teresa Giralt; Jerold Chun; Guillermo Estivill-Torrús; Fernando Rodríguez de Fonseca; Luis Javier Santín; Isidro Ferrer; Rafael Rodríguez-Puertas
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

9.  Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes.

Authors:  Luke M Healy; Graham K Sheridan; Adam J Pritchard; Aleksandra Rutkowska; Florian Mullershausen; Kumlesh K Dev
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

10.  Autotaxin: a secreted autocrine/paracrine factor that promotes glioma invasion.

Authors:  Dominique B Hoelzinger; Mitsutoshi Nakada; Tim Demuth; Tyler Rosensteel; Linsey B Reavie; Michael E Berens
Journal:  J Neurooncol       Date:  2007-10-11       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.